Experts say transparency needed for oversight of vaccine-makers

Experts called for more transparency in vaccine supervision after China's drug regulator disclosed on Tuesday that it had denied market access for more than 100,000 doses of rabies vaccine produced by two manufacturers in Jilin province.

Some 43,510 doses from Maifeng Bio Tech Co failed premarket checks of safety and effectiveness on Oct 29, as did 57,290 doses from Zhuoyi Biological Co on Nov 5. Both manufacturers are based in Changchun, Jilin.

The checks were conducted by the National Institutes for Food and Drug Control, which released the information about the substandard vaccines on its website.